BMS-955176
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection.By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been designed to better tolerate gag polymorphisms.[2][3] Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.